These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25972243)

  • 41. Ophiopogonin D' inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling.
    Xu T; Zhang W; Zhang Y; Song F; Huang P
    J Cell Mol Med; 2024 Aug; 28(16):e70014. PubMed ID: 39153211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
    Hu K; Zhang J; Yu M; Xiong C
    Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
    Che HY; Guo HY; Si XW; You QY; Lou WY
    Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
    Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.
    Hua SC; Chang TC; Chen HR; Lu CH; Liu YW; Chen SH; Yu HI; Chang YP; Lee YR
    Pharm Res; 2012 Jul; 29(7):1990-2005. PubMed ID: 22477067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of melatonin on the toxicity and proliferation of human anaplastic thyroid cancer cell line.
    Ghorbani-Anarkooli M; Dabirian S; Zendedel A; Moladoust H; Bahadori MH
    Acta Histochem; 2021 Apr; 123(3):151700. PubMed ID: 33667778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
    Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
    J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
    Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
    von Roemeling CA; Copland JA
    Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flavonoid Fraction of Citrus reticulata Juice Reduces Proliferation and Migration of Anaplastic Thyroid Carcinoma Cells.
    Celano M; Maggisano V; De Rose RF; Bulotta S; Maiuolo J; Navarra M; Russo D
    Nutr Cancer; 2015; 67(7):1183-90. PubMed ID: 26365817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
    Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
    Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
    Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
    Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
    Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.